For the Inventor, By the Inventor

Enter assignee name

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

USPTO Granted Patents = 118

CIPO Patents = 3

EPO Patents = 76

Trademarks = 3

Forward Citations = 99

Loading Chart...

Loading Chart...

383 inventors (with patents filed for the assignee):

Xiquan Zhang (38 out of 42 patents)

Hongjiang Xu (23 out of 27 patents)

Ling Yang (23 out of 27 patents)

4. Shuhui Chen (20 out of 196 patents)

5. Fei Liu (16 out of 17 patents)

6. Yongxin Han (15 out of 21 patents)

7. Rui Zhao (14 out of 16 patents)

8. Xin Tian (14 out of 16 patents)

9. Jian Li (13 out of 199 patents)

10. Yong Peng (12 out of 26 patents)

11. Yuandong Hu (12 out of 15 patents)

12. Aiming Zhang (11 out of 13 patents)

13. Shanchun Wang (11 out of 14 patents)

14. Hong Luo (11 out of 17 patents)

15. Charles Z Ding (10 out of 50 patents)

Core Competencies:

Quinoline Derivative

Antibody Therapy

KRAS G12C Inhibitor

TLR7 Agonist

BCL-2 Inhibitor

Capsid Protein Assembly Inhibitor

PDE3/PDE4 Dual Inhibitor

IRAK4 Inhibitor

Estrogen Receptor Antagonist

Triple-Negative Breast Cancer

Respiratory System Diseases

Androgen Receptor Antagonist

118 patents: Sort by Forward Citations

1. 12472173 - Quinoline derivative and antibody soft tissue sarcoma combination therapy (2025-11-18),

2. 12447154 - Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome (2025-10-21),

3. 12421313 - Combined pharmaceutical composition for treating tumor (2025-09-23),

4. 12421236 - Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor (2025-09-23),

5. 12390458 - Therapeutic combination of quinoline derivative and antibody (2025-08-19),

6. 12384745 - Crystal form of five-membered n heterocyclic compound, and application thereof (2025-08-12),

7. 12378192 - Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof (2025-08-05),

8. 12377089 - Quinoline derivative used for soft tissue sarcoma combination therapy (2025-08-05),

9. 12371431 - Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor (2025-07-29),

10. 12358927 - IRAK4 inhibitor crystal and preparation method therefor (2025-07-15),

11. 12358913 - Crystal of diarylthiohydantoin compound (2025-07-15),

12. 12358891 - Crystals of quinolone derivatives (2025-07-15),

13. 12357637 - Solid pharmaceutical composition comprising TLR7 agonist (2025-07-15),

14. 12336996 - Drug combination containing TLR7 agonist (2025-06-24),

15. 12319689 - Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor (2025-06-03),

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is a leading multinational pharmaceutical company. With a proven track record of over 30 years in the industry, the company specializes in the research, development, manufacturing, and marketing of innovative pharmaceutical and healthcare products. Chia Tai Tianqing is committed to enhancing human health and well-being by providing high-quality, affordable medicines for the global market. Visit their website for more information about their products and services.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

118 Patents

#5 in Jiangsu

#263 in China

#6,536 in the World

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Forward Citations = 99

383 inventors:

Xiquan Zhang (38 out of 42 patents)

Hongjiang Xu (23 out of 27 patents)

Ling Yang (23 out of 27 patents)

4. Shuhui Chen (20 out of 196 patents)

5. Fei Liu (16 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…